L-T 4 Bioequivalence and Hormone Replacement Studies via Feedback Control Simulations
The DOI matches its OpenAlex record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
FDA Guidance for testing bioequivalence of levothyroxine (L-T(4)) preparations has been challenged by several groups, based on multiple issues. The efficacy of single versus combined hormone therapy also is receiving additional scrutiny. To examine these concerns, we developed a new nonlinear feedback system simulation model of whole-body regulation mechanisms involving dynamics of T(3), T(4), TSH, plasma protein binding, extravascular regulatory enzyme systems, and the hypothalamic-pituitary-thyroid axis, all quantified from human data. To address bioequivalence, we explored how to best account for varying and unmeasured endogenous T(4) following dosing with exogenous oral L-T(4) in euthyroid volunteers in required pharmacokinetic (PK) studies, by simulating various dosing scenarios and developing a new and simple correction method. We computed and assessed dosing error effects and baseline corrections using simulator-predicted endogenous T(4) level variations, due to actual closed-loop effects, and compared these with approximate corrections computed directly from PK data. Predicted dose-responses were quite linear, and for constant baseline, 7-day half-life, and our new formula-correction methods, we established some bounds on bioequivalent dosages. Simulated replacement after thyroidectomy required 141 microg L-T(4) only to normalize T(3) tissue levels and 162 microg L-T(4) to normalize plasma T(3) levels. A combined dose of approximately 103 microg L-T(4) plus approximately 6 microg T(3) ( approximately 18:1 ratio) was needed to normalize both plasma T(3) and T(4) and average tissue T(3) levels. However, simulated average tissue T(3) levels were normalized with standard L-T(4)-only therapy, and plasma T(3) levels were still within the normal range. We suggest a simple and more accurate correction for endogenous T(4) in PK studies. Current standard L-T(4)-only treatment is supported for routine replacement needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bianco, A. C., Salvatore, D., Gereben, B., Berry, M. J., & Larsen, P. R. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0455 · Cited by 1,853
Bunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482 · cited 2×
“For additional simulation studies with oral T 3 þ T 4 , we assumed 98% of T 3 is absorbed (43,44).”
Fish, L. H., Schwartz, H. L., Cavanaugh, J., Steffes, M. W., Bantle, J. P., & Oppenheimer, J. H. (1987) · New England Journal of Medicine · doi:10.1056/nejm198703263161302 · Cited by 353
Escobar-Morreale, H. F., Botella-Carretero, J. I., Gómez-Bueno, M., Galán, J. M., Barrios, V., & Sancho, J. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-6-200503150-00007 · Cited by 182 · cited 4×
“Nevertheless, in principle, L-T 4 –alone treatment cannot restore normal T 3 levels in all tissues simultaneously (17), and actual tissue T 3 levels achieved using L-T 4 –alone treatment cannot be practically or ethically measured in patients.”
InfluentialWalsh, J. P., Ward, L. C., Burke, V., Bhagat, C. I., Shiels, L., Henley, D., Gillett, M. J., Gilbert, R., Tanner, M., & Stuckey, B. G. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0099 · Cited by 164
Treatment of Hypothyroidism with Combinations of Levothyroxine plus Liothyronine
Escobar-Morreale, H. F., Botella-Carretero, J. I., del Rey, F. E., & de Escobar, G. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0184 · Cited by 160
Aspects of the absorption of oral L-thyroxine in normal man
Wenzel, K. W., & Kirschsieper, H. E. (1977) · Metabolism · doi:10.1016/0026-0495(77)90121-4 · Cited by 151
Are Bioequivalence Studies of Levothyroxine Sodium Formulations in Euthyroid Volunteers Reliable?
Blakesley, V., Awni, W., Locke, C., Ludden, T., Granneman, G. R., & Braverman, L. E. (2004) · Thyroid · doi:10.1089/105072504773297867 · Cited by 85
Human Thyroxine Absorption: Age Effects and Methodological Analyses
HAYS, M. T., & NIELSEN, K. R. K. (1994) · Thyroid · doi:10.1089/thy.1994.4.55 · Cited by 67
Research works printed but not linked: 34
- 10.1089/1050725041517138 · DOI
- 10.1089/105072503321582088 · DOI
- 10.1208/aapsj070105 · DOI
- 10.1208/aapsj070106 · DOI
- 10.1208/aapsj070108 · DOI
- 10.1208/aapsj070107 · DOI
- Bahn RS, 2005, ATA Signal Newsl., 8, 1
- Food and Drug Administration 2003 Advisory Committee for Pharmaceutical Science, Record of Proceedings. Available at: http:==www.fda.gov=ohrms=dockets=ac=03=transcripts= 3926T2.pdf. Accessed January 8, 2006.
- 10.1089/105072504773297821 · DOI
- Katz MD, 1998, J Fam Pract, 46, 108
- 10.1210/er.23.1.38 · DOI
- Larsen PR, Davies TF, Schlumberger MJ, Hay ID 2003 Thyroid physiology and diagnostic evaluation of patients with thyroid disorders. In: Larsen PR (ed) Williams Textbook of Endocrinology, 10th ed. Saunders, Philadelphia, pp 331-373.
- Carr D, 1988, Clin Endocrinol (Oxf), 28, 325, 10.1111/j.1365-2265.1988.tb01219.x · DOI · Paper page
- 10.1056/NEJM199902113400611 · DOI · Paper page
- 10.1007/BF02476936 · DOI
- Cobelli C, 1986, Am J Physiol, 250, E591
- Mak PH, 1973, Endocrinology, 92, A244
- 10.1089/thy.2005.15.883 · DOI · Paper page
- DiStefano JJ, 1977, Am J Physiol, 233, R134
- 10.1007/BF02409340 · DOI
- DiStefano JJ, 1988, Endocrinology, 123, 2514, 10.1210/endo-123-5-2514 · DOI
- Hershman JM, 1986, Acta Endocrinol (Copenh), 111, 193, 10.1530/acta.0.1110193 · DOI · Paper page
- 10.1006/gcen.1996.0014 · DOI
- 10.1016/0025-5564(94)00054-4 · DOI
- 10.1016/0025-5564(84)90014-2 · DOI
- 10.1016/0025-5564(83)90070-6 · DOI
- Visser TJ, 1988, J Clin Endocrinol Metab, 67, 17, 10.1210/jcem-67-1-17 · DOI · Paper page
- DiStefano JJ, Fisher DA 1979 Peripheral distribution and metabolism of the thyroid hormones: a primarily quantitative assessment. In: Hershman J, Bray G (eds) The Thyroid: Physiology and Treatment of Disease, 1st ed. Pergamon Press, Elmsford, NY, pp 47-57.
- Kuku SF, 1975, Hormone Metab Res, 7, 54, 10.1055/s-0028-1093789 · DOI
- Lucke C, 1977, Acta Endocrinologica, 86, 81, 10.1530/acta.0.0860081 · DOI · Paper page
- DiStefano JJ, 1979, Am J Physiol, 236, R137
- Brent GA, Larsen PR 1996 Treatment of hypothyroidism. In: Braverman LE, Utiger RD (eds) Werner and Ingbar 0 s The Thyroid: A Fundamental and Clinical Text. Lippincott-Raven, Philadelphia, pp 883-887.
- Pilo A, 1990, Am J Physiol, 258, E715
- 10.1016/S0026-0495(98)90064-6 · DOI · Paper page
Cited by
Dietrich, J. W., Landgrafe-Mende, G., Wiora, E., Chatzitomaris, A., Klein, H. H., Midgley, J. E. M., & Hoermann, R. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00057 · Cited by 164
“Models based on the UCLA platform delivered an improved baseline correction method that is less prone to this kind of interference (27, 28).”
BackgroundMethodTSH and thyrotropic agonists: key actors in thyroid homeostasis
Dietrich, J. W., Landgrafe, G., & Fotiadou, E. H. (2012) · Journal of Thyroid Research · doi:10.1155/2012/351864 · Cited by 146
Levothyroxine Replacement Doses Are Affected by Gender and Weight, But Not Age
Devdhar, M., Drooger, R., Pehlivanova, M., Singh, G., & Jonklaas, J. (2011) · Thyroid · doi:10.1089/thy.2011.0029 · Cited by 90
Eisenberg, M., Samuels, M., & DiStefano, J. J. (2008) · Thyroid · doi:10.1089/thy.2007.0388 · Cited by 65
Self-citationCeli, F. S., Zemskova, M., Linderman, J. D., Babar, N. I., Skarulis, M. C., Csako, G., Wesley, R., Costello, R., Penzak, S. R., & Pucino, F. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03700.x · Cited by 65
Metadata
- Authors
- Eisenberg, M. C., Samuels, M. H., & DiStefano, J. J.
- Venue
- Thyroid
- Publisher
- SAGE Publications
- Published
- 2006-12
- Volume
- 16
- Issue
- 12
- Pages
- 1279-1292
- ISSN
- 1050-7256 (ISSN-L)
- OpenAlex
- W1989022508
- Cited by
- 31
- References
- 9
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.